Chief Executive Officer
|
|
- Grant Robinson
- 5 years ago
- Views:
Transcription
1 Said Darwazah Chief Executive Officer
2 211 highlights Strong Group performance in a challenging year 95 9 MSI PROMOPHARM $11.2 m $918.m BRANDED + 9.6% $37.9 m INJECTABLES % $36.7 m GENERICS % $19.7 m OTHER $.1m $786.6m $12.3 m 7 $73.9m Group Revenue Branded Injectables Generics Others 211 Organic Revenue MSI Promopharm 211 Group Revenue Page 1
3 Khalid Nabilsi Chief Financial Officer
4 Consolidated P&L Strong Group performance in a challenging g year $ million Change Revenue % Gross profit % Gross margin 43.1% 48.9% Operating profit % Adjusted 1 operating profit % Adjusted operating margin 15.9% 19.6% -3.7 Adjusted 2 net income % Basic EPS (cents) % Adjusted diluted EPS (cents) % Dividend per share (cents) Effective tax rate 11.1% 17.7% Page 3 1 Before the amortisation of intangible assets (excluding software) and exceptional items (including acquisition and integration costs of $16.4 million and an inventory adjustment of $1.8 million) 2 Before the amortisation of intangible assets (excluding software) and exceptional items
5 Branded Robust growth, despite the Arab Spring disruptions Revenue ($ million) 5 Organic 1 growth of 9.6%, ahead of 7% guidance % growth + 9.6% organic growth Egypt and Tunisia back to normal and recovery beginning in Libya Good growth across other key MENA markets Algeria, Sudan, Jordan, GCC 25 2 Successful completion of strategic acquisition in Morocco 15 1 Strengthened manufacturing capacity and capabilities in Sudan, Algeria, Egypt and Tunisia Page 4 1 Before the Promopharm acquisition
6 Branded Relatively stable operating margin despite inflationary pressure in MENA Gross profit ($ million) % Gross margin Change Reported 51.6% 48.4% Adjusted operating profit ($ million) % Operating margin Change Reported 25.% 22.3% Adjusted % 23.8% -.6 Page 5 1 Before the amortisation of intangible assets (excluding software) and exceptional items
7 Injectables Doubled Injectables sales to $316 million, with strong growth across all markets Injectables revenue by region ($ million) $ MSI MSI % % +14.2% $75.4 Promopharm USA Europe MENA Page 6
8 Injectables Excellent e improvement e in operating margin Gross profit ($ million) Adjusted operating profit ($ million) % % % 85. Injectables incl. MSI Injectables ex MSI % Injectables incl. MSI Injectables ex MSI Gross margin Change Reported 45.1% 4.4% Operating margin Change Reported 15.1% 14.4% -.7 Adjusted % 17.4% +.7 Organic % 17.5% Page 7 1 Before the amortisation of intangible assets (excluding software) and exceptional items 2 Before the MSI and Promopharm acquisitions
9 Generics Sales of $155 million, in line with guidance Revenue ($ million) 2 Reported sales declined by 11.3% % Excluding exceptional colchicine sales in 21, Generics achieved double-digit revenue growth in Strong volume growth was partially offset by accelerating pricing pressure Page 8
10 Generics Margin decline reflects exceptional benefit of colchicine sales in 21 Gross profit ($ million) Adjusted operating profit ($ million) % % Gross margin Change Reported 46.9% 33.7% Operating margin Change Reported 29.3% 11.% Adjusted % 11.1% 1% Page 9 1 Before the amortisation of intangible assets (excluding software)
11 Cash Flow Strong management of working capital Operating cash flow ($ million) 18 Group operating cash flow was $147.5 million, excluding the $21.1 million impact of the working capital financing for the MSI acquisition ex MSI 211 incl MSI Change Receivable days** (3) Inventory days (29) Payable days (12) Working capital days ** (2) 6 4 Operating Cash Flow / Sales 2.9% 16.1% 13.8% (7.1) 2 21 * 211 Page 1 * Group operating cash flow in the 21 Annual Report of $144.8 million has been adjusted to $152.5 million to exclude acquisition costs of $7.7 million in 21 and reclassify these within investing activities ** Certain items included within trade receivables in the 21 Annual Report have been reclassified. The calculations of receivable days and working capital days for 21 reflect these reclassifications
12 Capital expenditure Increased capex to support Branded and Injectables growth Capital expenditure ($ million) 8 Expansion of our manufacturing capacity and capabilities in MENA Algeria, Egypt and Tunisia % Machinery and equipment for our new lyophilisation facility in Portugal Investment in machinery and equipment for our MSI business MENA Europe US Page 11
13 Balance sheet Solid balance sheet after investments of $325 million in 211 Net debt position at 31 December 211 ($ million) Short-term borrowing Net debt Net debt/ebitda 2.55x.58x Net debt/equity.54x.14x Long-term borrowing Cash & cash equivalents Page 12
14 Summary Positive outlook for 212 Group revenue growth of around 2% Increased investment in R&D to be around 4.5% of Group sales Group finance expense of around $32 million Capital expenditure in the range of $85 million to $9 million Effective tax rate to be around 2%, reflecting the change in geographic sales mix Page 13
15 MENA REVIEW Said Darwazah Chief Executive Officer
16 Continuing to deliver strong growth and increase MENA market share Leading pharmaceutical companies in the MENA market Rank Unit sales Vl Value Avg Rx $ Growth Market share 211 (M) $M Price % % MENA PRIVATE MARKET 3,369 9, SANOFI GLAXOSMITHKLINE NOVARTIS PFIZER HIKMA PHARMA MERCK & CO SPIMACO ASTRAZENECA ABBOTT NOVO NORDISK Page 15 Source: IMS Healthcare YTD12/211. Private retail sales for 9 top MENA markets (Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE). Data excludes tender and injectables sales.
17 Despite Arab Spring, fundamental MENA growth drivers remain intact In May 211, the In December 211, interim Egyptian Saudi Arabia allocated Morocco announced the In March 211, the Jordanian Government agreed US4.4bn for investment in expansion of healthcare Government announced it to increase the the healthcare sector in assistance to benefit 8.5 had increased its social safety healthcare budget to January 212* million people** package in the 211 budget 11% of total by US$65m* expenditure* 21 YTD growth 3.% 211 YTD growth 25.% 2.% 15.% 1.% 5.%.% -5.% Egypt KSA Algeria Morocco UAE Lebanon Tunisia Jordan Kuwait MENA Page 16 Source: IMS Healthcare YTD12/211 and YTD 12/21. * Business Monitor International ** Epsicom Business Intelligence
18 Investment in facilities and people strengthens our MENA operations Morocco Total sales reps by country at December 211 Acquired local manufacturing facility Added 137 sales reps Added 22 products* Algeria Completed and inaugurated a new penicillin facility Tunisia Completed facilities upgrades to increase capacity and efficiency i Morocco 137 Tunisia 56 Algeria 186 Libya 28 Lebanon Jordan Egypt 44 Sudan 75 Syria 5 Iraq 42 Saudi Arabia 253 Yemen 4 Kuwait 8 Bahrain 7 & Qatar 7 UAE 5 Oman 9 Egypt Increased manufacturing capacity by 2% Sudan Acquired local manufacturing facility Added 48 products** Jordan Begun expansion of chemical facility Invested over $215 million in acquisitions and capex in MENA in 211 Page 17 * 192 of which are new products to Hikma ** 17 of which are new products to Hikma
19 Our robust business model limited the Arab Spring impact 211 revenue growth in Egypt, Tunisia and Libya Egypt and Tunisia benefitted from: 12.1% 1% Local manufacturing - Local management and sales teams - Experience of operating in politically unstable markets - Commitment to our employees (3.3%) (33.2%) Strength of our local team enabled swift re- entry into Libya Egypt Tunisia* Libya Page 18 Source: Hikma Branded and Injectables sales in 21 and 211 * Sales in 21 are proforma sales to include the full year effect of Ibn Al Baytar which was consolidated from April 21 on a reported basis
20 Growth in MENA Injectables will be driven by new product launches Targeted Injectables launches in key MENA markets, * Algeria Egypt GCC Iraq Jordan KSA Page 19 * Refers to the launch of new molecules in new markets, not including any additional launches of different dosage forms and strengths
21 Product portfolio development will be key growth driver in MENA Optimising product portfolio Focus on maximising sales of high value, high margin products Cut tail products New product launches More aggressive focus on the registration and launch of new products Identified 4 strategic molecules for fast track programme In-licensed partnerships Focus on building pipeline of products from existing in-license partners Develop new relationships and at different stages in the development process Unimark Leverage our investment in Unimark to supplement our in-house R&D activities Page 2
22 Successfully integrating Promopharm in Morocco 4th largest MENA market 8.7% growth in 211 Hikma people in place in Morocco supporting integration and business development opportunities Expected to growsales team from 137 to 2 by the end of 213 Begun work to register 2 strategic Hikma products in Morocco launch around 214 Potential MENA licensing opportunities Page 21
23 USA REVIEW
24 Injectables will be the key driver of future growth in the US US generics market value Product segment 211 Sales (value) 211 growth (%) No. of players (sales greater than $1 million) Orals $3.31bn Injectables $7.9bn Others $6.73bn +22.9% Total US Generics market $44.13bn +13.8% 48 Page 23 Source: IMS Health, National Sales Perspectives, YTD December 211
25 Developing an increasingly strong position in the US injectables market Top US generics injectables suppliers (million eaches) 6, 5, 41.2% 4, 3, 2, 17.3% 14.5% 1, 6.6% 4.2% 3.8% 3.4% 2.4% 1.4%.9%.9%.8% Page 24 Source : IMS Health MAT 12/211
26 Swift integration of the MSI business is delivering sales growth and increased profitability Headcount (FTE) Production units (millions) May % Headcount has been reduced by c.12% % Increased monthly production driven by restructuring of manufacturing processes and reorganisation of facilities Dec-11 May-11 Dec-11 Units produced per labour hour % Production cost per unit has significantly reduced as a result of headcount reductions and process efficiency improvements May-11 Dec-11 Page 25
27 Hikma s underlying US Injectables business is performing well US Injectables Total products marketed 211 US Injectables revenue excluding MSI 25 CNS Anti-infectives 15 Others, 16% Cardiovascular 13 Cardiovascular, CNS, 47% 17% Others Anti-infectives, 2% Page 26
28 Building a differentiated product pipeline to drive growth US Injectables product pipeline Pipeline ANDAs Dormant ANDAs R&D partnerships & differentiated products Products under- development Page 27
29 Increased scale of our global Injectables business is driving growth in Europe and MENA tender sales 211 Europe Injectables revenue ($ million) 9 Highly productive and efficient European facilities remain a key manufacturing hub % Portuguese facilities produce for US, Europe and MENA - New lyophilisation plant inaugurated in October Increased high value contract manufacturing opportunities in Europe - Benefiting from high quality reputation and track record of delivery 2 1 Increased scale is driving greater success in European and MENA tenders Page 28
30 Maintained market position in US oral generics market US generic oral market Orals 29 ( s) 21 ( s) 211( s) Total prescriptions written 2,49,483 2,576,24 2,76,71 Market growth +7.2% +6.9% +5.7% Hikma (West-Ward) Ward) Total prescriptions written 33,77 44,23 53,261 Growth +37.7% +3.9% +2.49% Total prescriptions written (excl. colchicine) 31,254 4,945 52,779 Growth (excl. colchicine) +32.5% +31.% +29% Hikma (West-Ward) rank Hikma (West-Ward) market share 1.4% 1.7% 1.95% Page 29 Source: IMS Health YTD December 211. Number of prescriptions filled in the US generics market for oral pharmaceuticals.
31 Short term focus on leveraging our MENA facilities. R&D investment driving future growth Percentage of Generics sales produced in MENA* US Generics product pipeline 3.% 25.% 5% 25.1% 21.2% 26.8% % 2 15.% 15 1.% 7.2% 9.4% 1 5.%.% Unimark** 2 R&D partnerships and differentiated products Pipeline ANDAs Products underdevelopment Page 3 * Oral generic products produced at our FDA approved facilities in Jordan and Saudi Arabia and sold in the US. Sales figures exclude colchicine ** Unimark brings a portfolio of potential ANDAs. We made 1 product submission in 211. We will begin the process for selecting additional submissions in 212.
32 CONCLUSION
33 Conclusion Group revenues ($ million) Acquired Baxter s Multi Source Injectables (US) in May 211 Acquired minority stake in Unimark (India) and Haosun (China) Acquired 94.1% of Promopharm in Morocco Acquired Elie Pharmaceuticals in Sudan Inauguration of Dar Al Arabia in Algeria HIKMA established in Jordan. Licenses from Fujisawa Japan Acquired Ibn Al Baytar/ Medicef In Tunisia Acquired Al Dar Al Arabia in Algeria Began manufacturing operations in Trust Pharma Algeria. Acquisition of the 52.5% of JPI not previously owned dby Hikma West-ward (US) acquired Hikma Farmaceutica (Portugal) established Started operations at Jazeera Pharmaceutical Industries (JPI) in Saudi Arabia) Acquired Ribosepharm and Thymoorgan (Germany) in H1 27. Acquired Alkan (Egypt) and APM (Jordan) in H2 27. Became public company listed on LSE. Acquired Hikma Italy. Hikma Pharma (Holding Co) established in Jersey. Acquired majority interest in clinical pharma research lab (IPRC) Page 32
34 Appendix
35 Revenue by segment and region 211 revenue by segment 211 revenue by region 48.1% 55.4% 16.9% 34.6%.6% 34.4% 1.% Branded Generics Injectables Other MENA US Europe & ROW Page 34
36 Injectables sales by region 211 Injectables revenue by region 51.4% 23.9% 24.8% MENA US Europe & ROW Page 35
37 Cash flow statement $ million Profit before tax and minority interest Adjustments for non-cash items Change in working capital (54.7) 4.7 Income tax paid (2.1) (32.7) Other Net cash generated from operating activities Investment in property, plant and equipment (69.) (49.1) Purchase of intangible assets (9.) (4.1) Acquisition of subsidiaries (217.8) (23.) Investment in associated companies (38.6) - Interest received.5.3 Other (9.6) (16.2) Net cash used in investing activities (343.5) (92.1) Issuance of new shares Change in debt (26.6) Dividends paid (25.2) (23.1) Interest paid (23.8) (13.8) Other (27.8) (1.1) Net cash generated from financing activities (61.2) Page 36
38 Balance sheet $ million Growth $ Growth % Cash % Trade and other receivables % Other current assets >119% Inventories % Total current assets % Intangible assets % Tangible fixed assets % Investment in associated companies and joint ventures >2% Other long-term assets % Total long-term assets % Total assets 1,576 1, % Financial debts and capital lease obligations % Trade accounts payable % Other current liabilities % Total current liabilities % Long-term financial debts and capital lease obligations >2% Other long-term liabilities % Total long-term liabilities >2% Total liabilities % Minority interest >2% Total shareholders equity % Total liabilities and shareholders equity 1,576 1, % Page 37
39 Branded Launching new products and developing markets Product launches in 211 Product approvals in MENA & ROW 1 1 Europe 3 5 MENA & ROW Europe New compounds New dosage forms and strengths Total product tlaunches New compounds New dosage forms and strengths Total product approvals Page 38
40 Branded Pipeline for future growth Product submissions in 211 Pending approvals in MENA & ROW Europe 5 MENA & ROW 3 4 Europe 14 New compounds New dosage forms and strengths Total submissions i New compounds New dosage forms and strengths Total pending approvals Page 39
41 Injectables Launching new products and developing new markets Product launches in 211 Product approvals in US MENA & ROW Europe US MENA & ROW Europe New compounds New compounds New dosage forms and strengths New dosage forms and strengths Total product tlaunches Total product approvals Page 4
42 Injectables Pipeline for future growth Product submissions in 211 Pending approvals in US MENA & ROW Europe US MENA & ROW Europe New compounds New dosage forms and strengths Total submissions i New compounds New dosage forms and strengths Total pending approvals Page 41
43 Generics Launching new products 1 Product launches in 211 Product approvals in US US New compounds New compounds New dosage forms and strengths Total product tlaunches New dosage forms and strength Total product approvals Page 42
44 Generics Pipeline for future growth Product submissions in 211 Pending approvals in US US New compounds New dosage forms and strengths Total submissions i New compounds New dosage forms and strengths Total pending approvals Page 43
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing
More informationHikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are
More informationCurrent trends in generic medicines in the Middle East: challenges and opportunities. Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC
Current trends in generic medicines in the Middle East: challenges and opportunities Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC Middle East and North African pharmaceutical markets Middle
More informationHikma Pharmaceuticals PLC. Meet the Management Day 15 November 2016
Hikma Pharmaceuticals PLC Meet the Management Day 15 November 2016 This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation.
More informationBetter health. Within reach. Every day.
Better health. Within reach. Every day. v Hikma Pharmaceuticals PLC 2018 Interim Results Hikma Pharmaceuticals PLC Group 1H18 financial highlights $989m $214m 21.6% 61.4 $185m Revenue Core 1 operating
More informationOverview. Highlights. Financial highlights
Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by
More informationOur core lies in quality, performance and courage
Our core lies in quality, performance and courage Tabuk Pharmaceuticals develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally, with a strong
More informationHikma s diversified business delivers record sales and 36% earnings growth in 2009
PRESS RELEASE Hikma s diversified business delivers record sales and 36% earnings growth in 2009 17 March 2010 ( Hikma ) (LSE: HIK) (NASDAQ DUBAI: HIK), the fast growing multinational pharmaceutical group,
More informationHikma Pharmaceuticals PLC Annual Report A strategy for growth
Hikma Pharmaceuticals PLC Annual Report 2005 A strategy for growth Hikma Pharmaceuticals PLC Contents 02 Group at a glance 04 Chairman and Chief Executive s review 06 Our strengths 14 Business and financial
More informationHIKMA PHARMACEUTICALS (HIK)
HIKMA PHARMACEUTICALS (HIK) Equity Research Report H1 2009 Results Update P.O. Box 930059, Amman 11193, Jordan Tel. + 962 (0) 6 5629300, Fax. + 962 (0) 6 5682941 www.abci.com.jo (A wholly owned subsidiary
More informationConstant currency numbers in 2016 represent reported 2016 numbers re-stated using average exchange rates in
PRESS RELEASE Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency London, 15 March 2017
More informationIntroduction to KUWAIT
Introduction to KUWAIT Kuwait is the world s 10th largest producer of oil. Total oil production, which is equivalent to half the country s GDP, was estimated at 2.9 million barrels per day in 2016. Oil
More informationBUILDING FOR THE FUTURE. Hikma Pharmaceuticals PLC Annual Report 2016
BUILDING FOR THE FUTURE Hikma Pharmaceuticals PLC Annual Report 2016 Contents Strategic report Overview IFC / At a glance Our business 2 / Chairman and Chief Executive s statement 4 / Our investment case
More informationIntroduction to SAUDI ARABIA
Introduction to SAUDI ARABIA Saudi Arabia is the world s largest oil producer and exporter with almost one-fifth of the word s proven oil reserves. Benefiting from abundant and cheap energy, the industrial
More informationHikma reports 2017 full year results
Press Release Hikma reports full year London, 14 March 2018 Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody s / BB+ S&P, both stable), the multinational
More informationIntroduction to MOROCCO
Introduction to MOROCCO With a GDP of USD 101bn in 2015, Morocco is a medium-sized economy. Sound macroeconomic fundamentals, a resilient and sophisticated banking sector and the implementation of structural
More informationInvestor Relations Presentation December 2012
Investor Relations Presentation December 2012 Contents 1. QNB at a Glance 2. QNB Comparative Positioning Qatar and MENA 3. Financial Highlights December 2012 4. Economic Overview 2 QNB at a Glance QNB
More informationDr. Raja M. Almarzoqi Albqami Institute of Diplomatic Studies
Dr. Raja M. Almarzoqi Albqami Institute of Diplomatic Studies Rmarzoqi@gmail.com 3 nd Meeting of OECD-MENA Senior Budget Officials Network Dubai, United Arab Emirates, 31 October-1 November 2010 Oil Exporters
More informationHikma delivers stable profitability and strong cash generation in H1 and maintains a solid balance sheet
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this
More informationWorking Group 1. Session 2: International Investment Agreements
Working Group 1 Session 2: International Investment Agreements 4 September 2007, Amman Dr. Alexander Böhmer OECD, Directorate for Financial and Enterprise Affairs What is the purpose of international investment
More informationRising Middle East Stock Markets
Rising Middle East Stock Markets Index, January 2002 = 100 1400 1200 1000 800 600 400 200 Egypt Israel Jordan Kuwait Saudi Arabia U.A.E. 0 2003 2004 2005 2006 Source: Bloomberg Capital Access Index 2006
More informationRegistration Insights & Pricing Structure Across The MENA Region. Mr Yahya A. Al jefri. CEO, Annahdah Medical Company, Saudi
1 Registration Insights & Pricing Structure Across The MENA Region 10-2017 Mr Yahya A. Al jefri. CEO, Annahdah Medical Company, Saudi AMC company profile 2 AMC establishment 3 Established in 1971, AMC
More informationHikma reports strong 2018 interim results and raises full year guidance
Press Release Hikma reports strong 2018 interim and raises full year guidance London, 15 August 2018 Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody
More informationFirst Half Results 2008:
First Half Results 2008: A strong performance in the first half ALMA gaining momentum August 4 th, 2008 First half results 2008 Agenda A strong performance in the first half ALMA gaining momentum John
More informationIntroduction to TUNISIA
Introduction to TUNISIA Tunisia is small open economy with strong ties to Europe. The country has been cited as a success story for a number of years, following decades of robust growth and impressive
More informationNORTH AFRICA HOLDING COMPANY
NORTH AFRICA HOLDING COMPANY Unlocking Potential Creating Value CORPORATE PRESENTATION December 2010 1 Agenda North Africa Holding Company Why investing in North Africa KIPCO Group 2 Snapshot on North
More informationMENA Benchmarking Report Arab-EU Business Facilitation Network
MENA Benchmarking Report Arab-EU Business Facilitation Network www.ae-network.org September 2014 Agenda Objective of the Report Macroeconomic Analysis Business Environment Index MENA Rankings 2 Objective
More informationImproving the Business Environment in Iraq Through Secured Transactions
Improving the Business Environment in Iraq Through Secured Transactions Murat Sultanov Beirut, October 17, 2011 CONTENTS What is Secured Transactions? Economic Importance 1 Why these systems are underdeveloped
More informationRe-assessing the Arab-European Financial Relationship: Continuity in the Middle East, Change in Europe
Re-assessing the Arab-European Financial Relationship: Continuity in the Middle East, Change in Europe Andrew Cunningham Founder Darien Middle East www.darienmiddleeast.com French-Arab Banking Dialogue
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationJuly Bayt.com Happiness Survey in Middle East and North Africa
July 2013 Bayt.com Happiness Survey in Middle East and North Africa Objective The research was conducted to understand the current level of happiness and satisfaction in the MENA region. The key information
More informationLaboratorios Farmacéuticos ROVI
Laboratorios Farmacéuticos ROVI Becat on track; guidance uplifted Q3 results Pharma & biotech Laboratorios Farmacéuticos ROVI (ROVI) has reported 9M18 operating revenue of 218.9m (+7.6% y-o-y), driven
More informationThis presentation is not an offer or invitation to subscribe for or purchase any securities.
Disclaimer This presentation is not an offer or invitation to subscribe for or purchase any securities. No warranty is given as to the accuracy or completeness of the information in this presentation.
More informationBayt.com Middle East Consumer Confidence Index. September 2016
Bayt.com Middle East Consumer Confidence Index September 2016 Section 1 PROJECT BACKGROUND Objectives To understand perceptions and attitudes of consumers in the Middle East regarding the economy of their
More informationInvestment Development Authority of Lebanon Arab Spanish Investment Forum 2011
Investment Development Authority of Lebanon Arab Spanish Investment Forum 2011 Wednesday October 26 th Headlines 1. ABOUT LEBANON 2. CURRENT TRENDS IN SPANISH LEBANESE TRADE 3. SPANISH COMPANIES AND LEBANON
More informationASX Announcement MAYNE PHARMA REPORTS RECORD FY14 RESULT
MAYNE PHARMA REPORTS RECORD FY14 RESULT 27 August 2014, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to release its consolidated results for the year ended 30 June 2014. The Group
More informationAgenda. Financial Review. Review of Operations. Future Plans and Strategies. Open Forum
22 October 2009 1 Disclaimer The information contained in this presentation is intended solely for your personal reference. Such information is subject to change without notice, its accuracy is not guaranteed
More informationDelivering mobile connectivity in MENA: A review of mobile sector taxation and licence extension. May 2017
Delivering mobile connectivity in MENA: A review of mobile sector taxation and licence extension May 2017 Executive Summary The report provides an overview of the tax and fee regime applied to mobile services
More informationPAYMENT SYSTEMS IN THE ARAB COUNTRIES
PAYMENT SYSTEMS IN THE ARAB COUNTRIES -Africa- WORLD BANK CONFERENCE REDEFINING THE LANDSCAPE OF PAYMENT SYSTEMS 7-10 APRIL 2009 CAPE TOWN-SOUTH AFRICA RAMZY HAMADEH 1 PAYMENT SYSTEMS IN THE ARAB COUNTRIES
More informationThe Bayt.com Middle East and North Africa Salary Survey May 2018
The Bayt.com Middle East and North Africa Salary Survey 0 May 0 Objectives The research was conducted to gauge employee satisfaction with their current salaries and factors affecting thereof. The key objectives
More informationForeign Investment Statistics
2012-2013 Released Date: May 2015 Table of Contents Introduction....4 Key Points......5 Total Stock of Foreign Investment (FI) by Economic Activity....6 Foreign Direct Investment (FDI) by Economic Activity.......8
More informationInvestor Relations Presentation December 2013
Investor Relations Presentation December 2013 Contents 1. QNB at a Glance 2. QNB Comparative Positioning Qatar and MENA 3. Financial Highlights as at 31 December 2013 4. Economic Overview Notes: These
More informationThe Bayt.com Middle and North Africa Salary Survey May 2014
The Bayt.com Middle and North Africa Salary Survey 2014 May 2014 Objective The research was conducted to gauge employee satisfaction of their current salaries and factors affecting thereof. The key objectives
More informationMSCI Index Proposal for Gulf Countries. November 2005
MSCI Index Proposal for Gulf Countries November 2005 Introduction This document sets forth MSCI s proposal to create indices for the countries of the Gulf Cooperation Council (GCC). MSCI is considering
More informationTHE PRIVATE SECTOR ARM OF THE ISLAMIC DEVELOPMENT BANK GROUP
THE PRIVATE SECTOR ARM OF THE ISLAMIC DEVELOPMENT BANK GROUP 3rd International Conference on Foreign Investment in Albania Islamic Corporation for the Development of the Private Sector (ICD) Member of
More informationInvestor Relations Presentation September 2017
Investor Relations Presentation September 2017 Contents 1. QNB at a Glance 2. QNB Comparative Positioning Qatar and MEA 3. Financial Highlights as at 30 September 2017 4. Economic Overview Notes: All figures
More informationArab Bank Group INVESTOR RELATIONS PRESENTATION. December 31, 2017
Arab Bank Group INVESTOR RELATIONS PRESENTATION December 31, 2017 1 TABLE OF CONTENTS General Information Financial Data & KPIs Credit Rating Stock Information Corporate Governance Disclaimer Appendix
More informationThe MENA-OECD Investment Programme Investment in the MENA Region and the Crisis
The MENA-OECD Investment Programme Investment in the MENA Region and the Crisis Amman, 15 February 2010 Agenda 1. Effects of the crisis and the work of the OECD 2. Macroeconomic trends in the MENA region
More informationBilateral agreements on investment promotion and protection
Bilateral agreements on investment promotion and protection Country Date Signed Entry into force South Africa 26 April 2005 - Albania 30 October 1993 - Algeria 7 July 2006 - Germany 20 December 1963 6
More informationAfrica & Middle East. September rd CLSA Investors Forum Sunil Kaushal Regional CEO, Africa & Middle East
Africa & Middle East September 2016 23 rd CLSA Investors Forum Sunil Kaushal Regional CEO, Africa & Middle East 0 Forward looking statements This document contains or incorporates by reference forward-looking
More informationPresentation. 2013/14 Annual Results. 17 September 2014
Corporate Presentation 2013/14 Annual Results 17 September 2014 Disclaimer The information contained in this presentation is intended solely for your personal reference. Such information is subject to
More informationLEBANON WEEKLY REPORT
Lebanon s major entrepreneurship weakness is in product innovation, being the ability to provide unique products or services. The country s greatest strength in entrepreneurship is found in its perception
More informationArab Bank Group INVESTOR RELATIONS PRESENTATION. December 31, 2016
Arab Bank Group INVESTOR RELATIONS PRESENTATION December 31, 2016 1 TABLE OF CONTENTS General Information Financial Data & KPIs Credit Rating Stock Information Corporate Governance Disclaimer Appendix
More informationMiddle East and North Africa Regional Economic Outlook Oil, Conflicts, and Transitions
Middle East and North Africa Regional Economic Outlook Oil, Conflicts, and Transitions May 5, 2015 Agenda Global Environment MENAP Oil Exporters MENAP Oil Importers Global growth remains moderate and uneven
More informationSTRENGTHENING CAPITAL MARKET REGULATION AND SUPERVISION IN THE MENA REGION
MENA-OECD CAPITAL MARKETS TASK FORCE MEETING ON STRENGTHENING CAPITAL MARKET REGULATION AND SUPERVISION IN THE MENA REGION 22 May 2012, starting at 14.00 Rotana Beach Hotel PRECEDING THE AMF-IMF-WORLD
More informationVAT IN UAE GENERAL UNDERSTANDING.
VAT IN UAE GENERAL UNDERSTANDING Introduction of VAT Value Added Tax (VAT) is an indirect tax on consumption. It applies to most goods and services. VAT is levied on business transactions, i.e. on goods
More informationLavendon Group plc European and Middle Eastern Market Leader for Powered Access Rental
Lavendon Group plc European and Middle Eastern Market Leader for Powered Access Rental 2015 Full Year Results Presentation 25 February 2016 25 February 2016 2015 Full Year Results Agenda Overview Financial
More informationMEIC PRE-CONFERENCE SURVEY MIDDLE EAST & NORTH AFRICA MARKET ISSUES. 6 April 2014
MEIC PRE-CONFERENCE SURVEY MIDDLE EAST & NORTH AFRICA MARKET ISSUES 6 April 2014 SURVEY RESULTS 80% EXPECT THEIR LOCAL ECONOMY TO EXPAND IN 2014, 76% EXPECT THEIR BUSINESS TO EXPAND AND 67% EXPECT THE
More informationHSBC Holdings plc Annual Results
HSBC Holdings plc Forward-looking statements This presentation and subsequent discussion may contain certain forward-looking statements with respect to the financial condition, results of operations and
More information2010 Results. Paris - March 2, 2011
2010 Results Paris - March 2, 2011 > Highlights of 2010 > Financial results > Strategy and outlook 2010 Results 2 2010: A Year of Acceleration Highlights of 2010 Revenue of 3,892m, up 19.1% Operating profit
More informationZain Group Financial Results Q4 2017
Zain Group Financial Results Q4 2017 Disclaimer Mobile Telecommunications Company KSCP Zain Group has prepared this presentation to the best of its abilities, however, no warranty or representation, express
More informationMEIC PRE-CONFERENCE SURVEY: MIDDLE EAST & NORTH AFRICA MARKET ISSUES. March 2013
MEIC PRE-CONFERENCE SURVEY: MIDDLE EAST & NORTH AFRICA MARKET ISSUES March 2013 SURVEY RESULTS POLITICAL STABILITY & GOOD GOVERNANCE WOULD HAVE THE MOST POSITIVE IMPACT ON ECONOMY 60% What do you think
More informationMiddle East and North Africa Regional Economic Outlook
Regional Economic Outlook Morocco Algeria Tunisia Libya Lebanon Egypt Syria Iraq Iran Jordan Saudi Kuwait Arabia Bahrain Afghanistan Pakistan Mauritania Sudan Djibouti Qatar Yemen Oman United Arab Emirates
More informationThe Food Travel Experts.
The Food Travel Experts www.foodtravelexperts.com SSP Group plc Annual Results 2016 29 November 2016 Presentation structure 1. Group highlights Kate Swann 2. Financial review Jonathan Davies 3. Business
More informationIndependent auditors report to the members of Hikma Pharmaceuticals plc
Financial statements We continue to deliver accurate, high-quality and timely information to all stakeholders with the utmost integrity and efficiency. 113 Independent auditors report 122 Consolidated
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationThe UAE has the least demanding tax system, but new data highlights post filing challenges for the region, says PwC
The UAE has the least demanding tax system, but new data highlights post filing challenges for the region, says PwC Qatar and the UAE currently share equal first place globally as the easiest countries
More information2016 Preliminary Results
2016 Preliminary Results 23 February 2017 Crown copyright All statements other than statements of historical fact included in this document, including, without limitation, those regarding the financial
More information- Net sales amounted to SEK 36.1 million (26.4), an increase of SEK 9.7 million (37%) compared to the same period of last year.
Press Release, 22 April 2008 (10 pages) BioGaia AB Interim report 1 January 31 March 2008 (Figures in brackets refer to the same period of the previous year) - Net sales amounted to SEK 36.1 million (26.4),
More informationLebanon Weekly Report
ECONOMY World Bank forecasts Lebanon real GDP growth at 2% in 2015 and 2.5% in 2016 The World Bank said that Lebanon s economic activity continues to tick along at a modest pace despite the political dysfunctionality.
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationNTDEC EXECUTIVE FORUM. Current Conflicts in Middle East
NTDEC EXECUTIVE FORUM Current Conflicts in Middle East Presented by the North Texas District Export Council October 21. 2014 By Riad SUKKAR International Business Development AMC Global Topics Conflicts
More informationImportance of financial infrastructure to increase Access to Finance
Building a high performance SME business in the MENA Region Arab Monetary Fund & International Finance Corporation Dubai, 7-8 May 2013 Importance of financial infrastructure to increase Access to Finance
More informationArab Bank Group. Investor Relations Presentation June 30, 2016
Arab Bank Group Investor Relations Presentation June 30, 2016 1 General Information Financial Data & KPIs Q2 2016 Key Performance Extracts Credit Rating Table of Contents Stock Information Corporate Governance
More information/JordanStrategyForumJSF Jordan Strategy Forum. Amman, Jordan T: F:
The Jordan Strategy Forum (JSF) is a not-for-profit organization, which represents a group of Jordanian private sector companies that are active in corporate and social responsibility (CSR) and in promoting
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited HY14 Results Presentation 26 February 2014 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO Disclaimer The information provided is general in nature and is in
More informationQ4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017
Q4 FY16-17 EARNINGS PRESENTATION 29 th May 2017 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationDr. Reddy s Laboratories Ltd Q3 FY12 Press Meet. February 03, 2012
Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet February 03, 2012 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationMENA DEALS INSIGHT 1Q 2015
Q1 MENA DEALS INSIGHT 1Q 2015 Quarter Highlights MENA Deal Insight 1Q2015 MENA M&A to maintain healthy growth into 2015: EY UAE seen leading mergers in the Middle East region 2014 IPOs close on a positive
More informationAlgeria's GDP growth is expected to stand at 3.5%, inflation at 7.5% for 2018.
Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Key Messages: MENA Economic Monitor- April 2018 Economic growth in MENA is projected
More informationComperative DTTs of Pakistan
Comperative DTTs of Pakistan 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 S. No. COUNTRY CONTINENT Republic/Dem ocratic/kingdo m/sultanate P.E. BUSINESS PROFIT SHIPPING AIR TRANSPORT DIVIDEND INTEREST ROYALITIES
More informationSwitzerland Economic Update QNB Group. September 2014
Switzerland Economic Update QNB Group September 14 Switzerland Overview Switzerland s efficient capital markets, highly skilled human capital and low corporate tax rates make it the world's most competitive
More informationA broken social contract, not inequality, triggered the Arab Spring
A broken social contract, not inequality, triggered the Arab Spring Shanta Devarajan and Elena Ianchovichina World Bank www.brookings.edu/futuredevelopment % of population Before 2011, poverty rates in
More informationInvestor Relations Presentation April 2012
Investor Relations Presentation April 2012 Contents 1. QNB at a Glance 2. Qatar Banking Sector 3. Financial Highlights March 2012 4. Economic Overview 2 QNB at a Glance QNB at a Glance: Overview Overview
More informationYouGov plc. Results in line with expectations
YouGov plc Solid progress in challenging market conditions Results in line with expectations Interim results to Interim results to 31 January 2010 Overview Continuing challenging period for the market
More informationNASCO KARAOGLAN FRANCE
NASCO KARAOGLAN FRANCE NKF VALUES WHO ARE WE? NASCO GROUP NASCO FRANCE TREATY DEPARTMENT NASCO FRANCE NK France was founded in 1976 in Paris as a wholly owned subsidiary of Nasco Karaoglan Group. The Company
More information26 MAY Boustead Singapore Limited FY2010 Financial Results Presentation
26 MAY 2010 Boustead Singapore Limited FY2010 Financial Results Presentation Disclaimer This presentation contains certain statements that are not statements of historical fact such as forward-looking
More informationFor personal use only
MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group
More information2017 Full Year Results. Tuesday 21 November 2017
2017 Full Year Results Tuesday 21 November 2017 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause
More informationInterim Results 17 November 2011
Interim Results 17 November 2011 Alan Parker Executive Chairman First 100 days Considerations: Group leadership and strategy Business model, at home and abroad Customer attraction in different markets
More informationPreliminary Results 2013 Imperial Tobacco Group PLC
Preliminary Results 2013 Imperial Tobacco Group PLC 5 November 2013 1 Disclaimer Certain statements in this document constitute or may constitute forward-looking statements. Any statement in this document
More information2013 Interim Results. 14 August 2013
2013 Interim Results 14 August 2013 1 This presentation contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives.
More informationZain Group Financial Results Q3 2018
Zain Group Financial Results Q3 2018 2 Disclaimer Mobile Telecommunications Company KSCP Zain Group has prepared this presentation to the best of its abilities, however, no warranty or representation,
More informationIndonesia Economic Update QNB Group. October 2014
Indonesia Economic Update QNB Group October 214 Indonesia Overview The economy has enormous long-term potential based on a rich endowment of natural resources and a large population; the new Jokowi administration
More informationA Review of Intellectual Property-Related News and Developments in the Middle East and North Africa March 2013 issue 3
Bulletin A Review of Intellectual Property-Related News and Developments in the Middle East and North Africa March 2013 issue 3 NEWS: Ethiopia - New Law Comes Into Effect The long-awaited regulations implementing
More informationJanuary March Conference Call. Georg Denoke Member of the Executive Board & CFO 4 May 2011
January March 2011 Conference Call Georg Denoke Member of the Executive Board & CFO 4 May 2011 Disclaimer This presentation contains forward-looking statements about Linde AG ( Linde ) and their respective
More informationAlembic Pharmaceuticals Ltd
Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe
More informationEdita Food Industries Reports FY2018 Earnings
Edita Food Industries Reports FY2018 Earnings Edita delivers a strong 24.1% increase in FY2018 revenues to EGP 3.8 billion as volumes continue to grow along with improved profitability. EBITDA margin in
More informationKONE Financial Statements 2007 January 25, 2008 President & CEO Matti Alahuhta. KONE Corporation
KONE Financial Statements 2007 January 25, 2008 President & CEO Matti Alahuhta 1 KONE Corporation Q4 High growth in orders received and operating income continued 10-12/2007 10-12/2006 Historical change
More informationAnnual General Meeting July 20, 2017
Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future
More information